Gilead's Covid-19 drug remdesivir to cost $2,340 per patient in US

Gilead Sciences Inc has priced its Covid-19 drug candidate remdesivir at $390 per vial for the United States and governments of other developed countries, it said on Monday, setting the price of a five-day course at $2,340 per patient.

The price for US private insurance companies will be $520 per vial, the drugmaker said, which equates to a total of $3,120 per patient.

Gilead has entered into an agreement with the US Department of Health and Human Services (HHS) whereby the department and states will manage allocation to hospitals until September end.

After this period, once supplies are less constrained,